{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:51:03Z","timestamp":1786989063605,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":5851,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.exphem.2006.02.020","type":"journal-article","created":{"date-parts":[[2006,6,8]],"date-time":"2006-06-08T14:17:16Z","timestamp":1149776236000},"page":"770-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status"],"prefix":"10.1016","volume":"34","author":[{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Zabelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Schieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Renges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2006.02.020_bib1","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kr\u00f6ger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2141.2001.02599.x","article-title":"Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma","volume":"112","author":"Kr\u00f6ger","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2006.02.020_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.leu.2403252","article-title":"Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma","volume":"18","author":"Ayuk","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2006.02.020_bib6","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib7","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2004-05-2031","article-title":"Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma","volume":"104","author":"Kr\u00f6ger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib8","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2006.02.020_bib9","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced intensity conditioning with pretransplant anti-thymocyte globulin is highly effective with low transplantation related mortality","volume":"100","author":"Kr\u00f6ger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant","volume":"102","author":"Blade","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2006.02.020_bib11","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2006.02.020_bib12","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2006.02.020_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib14","first-page":"149a","article-title":"Peripheral neuropathy following bortezomib (VELCADE, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility","volume":"102","author":"Richardson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2006.02.020_bib16","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2006.02.020_bib17","first-page":"278","article-title":"Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation","volume":"90","author":"Patriarca","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2006.02.020_bib18","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/sj.leu.2403855","article-title":"Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect","volume":"19","author":"Paubelle","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2006.02.020_bib19","first-page":"581","article-title":"Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM)","volume":"22","author":"Berenson","year":"2003","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X06001275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X06001275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:22:02Z","timestamp":1759566122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X06001275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0301472X06001275"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2006.02.020","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2006.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}